Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific is well positioned by a broad, differentiated portfolio in MedSurg and Cardiovascular, with a steady cadence of new products and multiple launch-driven tailwinds such as Farapulse, Watchman LAA, and AGENT DCB. Its growth case is strengthened by a long-term secular sales acceleration cycle, above-MedTech industry growth, and continued expansion into higher-growth markets through internal development and tuck-in M&A. The company’s global reach, including roughly 36% of sales from foreign markets, and gradual operating margin improvement support the view that earnings and top-line momentum can remain durable despite competitive and macro risks.

Boston Scientific is facing a materially weaker fundamental setup after the August 25, 2026 cyberattack disrupted roughly 9% of revenue-producing days, forcing management to signal it was unlikely to meet prior sales-growth and adjusted-EPS guidance. The fallout appears to be pressuring both revenue and profitability, with estimates cut about 10% for 3Q26, gross margin hit by higher COGS and inventory pressure, and 3Q26 EPS reduced to $0.58 from $0.81. Beyond the breach, competitive pressure in LAAC and EP, plus a lower organic long-range plan of 50-100 bps, suggests execution missteps and a tougher recovery path that could keep investor confidence subdued.